SARS-CoV-2 seroprevalence and associated risk factors in periurban Zambia: a population-based study.
COVID-19
Population-based survey
SARS-CoV-2
Seroprevalence
TB/HIV
Zambia
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
22
12
2021
revised:
10
03
2022
accepted:
12
03
2022
pubmed:
21
3
2022
medline:
29
4
2022
entrez:
20
3
2022
Statut:
ppublish
Résumé
We nested a seroprevalence survey within the TREATS (Tuberculosis Reduction through Expanded Antiretroviral Treatment and Screening) project. We aimed to measure the seroprevalence of SARS-CoV-2 infection and investigate associated risk factors in one community (population ∼27,000) with high prevalence of TB/HIV in Zambia. The study design was cross-sectional. A random sample of 3592 individuals aged ≥15 years enrolled in the TREATS TB-prevalence survey were selected for antibody testing. Randomly selected blocks of residence were visited between October 2020 and March 2021. Antibodies against SARS-CoV-2 were detected using Abbott- ARCHITECT SARS-CoV-2 IgG assay. A total of 3035/3526 (86.1%) individuals had a blood sample taken. Antibody testing results were available for 2917/3035 (96.1%) participants. Overall, 401/2977 (13.5%) individuals tested positive for IgG antibodies. Seroprevalence was similar by sex (12.7% men vs 14.0% women) and was lowest in the youngest age group 15-19 years (9.7%) and similar in ages 20 years and older (∼15%). We found no evidence of an association between seroprevalence and HIV-status or TB. There was strong evidence (p <0.001) of variation by time of enrollment, with prevalence varying from 2.8% (95% CI 0.8-4.9) among those recruited in December 2020 to 33.7% (95% CI 27.7-39.7) among those recruited in mid-February 2021. Seroprevalence was 13.5% but there was substantial variation over time, with a sharp increase to approximately 35% toward the end of the second epidemic wave.
Sections du résumé
BACKGROUND
BACKGROUND
We nested a seroprevalence survey within the TREATS (Tuberculosis Reduction through Expanded Antiretroviral Treatment and Screening) project. We aimed to measure the seroprevalence of SARS-CoV-2 infection and investigate associated risk factors in one community (population ∼27,000) with high prevalence of TB/HIV in Zambia.
METHODS
METHODS
The study design was cross-sectional. A random sample of 3592 individuals aged ≥15 years enrolled in the TREATS TB-prevalence survey were selected for antibody testing. Randomly selected blocks of residence were visited between October 2020 and March 2021. Antibodies against SARS-CoV-2 were detected using Abbott- ARCHITECT SARS-CoV-2 IgG assay.
RESULTS
RESULTS
A total of 3035/3526 (86.1%) individuals had a blood sample taken. Antibody testing results were available for 2917/3035 (96.1%) participants. Overall, 401/2977 (13.5%) individuals tested positive for IgG antibodies. Seroprevalence was similar by sex (12.7% men vs 14.0% women) and was lowest in the youngest age group 15-19 years (9.7%) and similar in ages 20 years and older (∼15%). We found no evidence of an association between seroprevalence and HIV-status or TB. There was strong evidence (p <0.001) of variation by time of enrollment, with prevalence varying from 2.8% (95% CI 0.8-4.9) among those recruited in December 2020 to 33.7% (95% CI 27.7-39.7) among those recruited in mid-February 2021.
CONCLUSION
CONCLUSIONS
Seroprevalence was 13.5% but there was substantial variation over time, with a sharp increase to approximately 35% toward the end of the second epidemic wave.
Identifiants
pubmed: 35306205
pii: S1201-9712(22)00158-8
doi: 10.1016/j.ijid.2022.03.021
pmc: PMC8925090
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
256-263Subventions
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Emerg Infect Dis. 2021 Aug;27(8):2166-2168
pubmed: 34287124
N Engl J Med. 2019 Jul 18;381(3):207-218
pubmed: 31314965
Ann Intern Med. 2020 Sep 15;173(6):450-460
pubmed: 32496919
Rev Med Virol. 2022 Mar;32(2):e2271
pubmed: 34228851
Lancet Glob Health. 2021 Jun;9(6):e773-e781
pubmed: 33711262
MMWR Morb Mortal Wkly Rep. 2021 Jun 04;70(22):807-810
pubmed: 34081684
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
PLoS One. 2021 Feb 25;16(2):e0247852
pubmed: 33630977
Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015
pubmed: 32860699
Int J Infect Dis. 2020 Dec;101:314-322
pubmed: 33045429
J Hosp Infect. 2021 Feb;108:120-134
pubmed: 33212126
BMC Infect Dis. 2020 Oct 9;20(1):744
pubmed: 33036570
Sci Rep. 2021 Mar 18;11(1):6283
pubmed: 33737527
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652
pubmed: 32584464
Int J Legal Med. 2020 Jul;134(4):1275-1284
pubmed: 32500199
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Lancet Glob Health. 2021 May;9(5):e598-e609
pubmed: 33705690
Int J Infect Dis. 2021 Sep;110:141-150
pubmed: 34273518
J Clin Virol. 2020 Aug;129:104539
pubmed: 32679298
Nicotine Tob Res. 2021 Aug 4;23(8):1398-1404
pubmed: 33420786
Eur Respir J. 2021 Mar 4;57(3):
pubmed: 32732325
PLoS One. 2021 Jun 23;16(6):e0252617
pubmed: 34161316
Clin Microbiol Infect. 2021 Mar;27(3):331-340
pubmed: 33228974
Lancet Glob Health. 2020 Nov;8(11):e1390-e1398
pubmed: 32979314
Open Forum Infect Dis. 2020 Nov 03;7(12):ofaa535
pubmed: 33349793
BMJ. 2021 Feb 17;372:n334
pubmed: 33597166
Clin Infect Dis. 2021 Sep 15;73(6):e1321-e1328
pubmed: 33784382
Int J Infect Dis. 2021 Aug;109:160-167
pubmed: 34320461
Cardiovasc Drugs Ther. 1990 Mar;4 Suppl 2:395-402
pubmed: 2271401